Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer

Cell Death and Disease

Volumn 7, Issue , 2016, Pages e2057-

  Akimoto, M ^a   Hayashi, J I ^b   Nakae, S ^c   Saito, H ^d   Takenaga, K ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALARMIN; ALPHA SMOOTH MUSCLE ACTIN; BETA ACTIN; CYTOKINE; GAMMA INTERFERON; I KAPPA B ALPHA; I KAPPA B BETA; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; RAPAMYCIN; ST2L PROTEIN; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; DOWN REGULATION; IMMUNOFLUORESCENCE; IN VITRO STUDY; LEWIS CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; WILD TYPE; ANIMAL; GENETIC TRANSFECTION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM;

ANIMALS; HUMANS; INTERLEUKIN-33; LUNG NEOPLASMS; MICE; NEOPLASM METASTASIS; TRANSFECTION; TUMOR MICROENVIRONMENT;

EID: 84955123433     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.418     Document Type: Article

References (47)

1. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490.
2. Onda. H, Kasuya H, Takakura K, Hori T, Imaizumi T, Takeuchi T et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab 1999; 19: 1279-1288.
3. Baekkevold ES, Roussigné M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003; 163: 69-79.
4. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS ONE 2008; 3: e3331.
5. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339-346.
6. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103-110.
7. Haraldsen G, Balogh J, Pollheimer J, Sponhiem J, Kuchler AM. Interleukin-33-cytokine of dual function or novel alarmin? Trends Immunol 2009; 30: 227-233.
8. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 2002; 32: 1520-1526.
9. Xu D, Chan WL, Leung BP, Huang Fp, Wheeler R, Piedrafita D et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998; 187: 787-794.
10. Chan WL, Pejnovic N, Lee CA, Al-Ali NA. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol 2001; 167: 1238-1244.
11. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm 2011; 8: 22.
12. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011; 7: 321-329.
13. Lefrancais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA 2012; 109: 1673-1678.
14. Luzina IG, Pickering EM, Kopach P, Kang PH, Lockatell V, Todd NW et al. Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol 2012; 189: 403-410.
15. Tominaga S, Jenkins NA, Gilbert DJ, Copeland NG, Tetsuka T. Molecular cloning of the murine ST2 gene: characterization and chromosomal mapping. Biochim Biophys Acta 1991; 1090: 1-8.
16. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994; 13: 1176-1188.
17. Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, Yashiro T et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2LV. Biochem Biophys Res Commun 2001; 285: 1377-1383.
18. Fujita J, Kawaguchi M, Kokubu F, Ohara G, Ota K, Huang SK et al. Interleukin-33 induces interleukin-17 F in bronchial epithelial cells. Allergy 2012; 67: 744-750.
19. Yagami A, Orihara K, Morita H, Futamura K, Hashimoto N, Matsumoto K et al. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol 2010; 185: 5743-5750.
20. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010; 107: 8017-8022.
21. Lin J, Zhao GQ, Wang Q, Xu Q, Che CY, Hu LT et al. Regulation of interleukin 33/ST2 signaling of human corneal epithelium in allergic diseases. Int J Ophthalmol 2013; 6: 23-29.
22. Zhao J, Wei J, Mialki RK, Mallampalli DF, Chen BB, Coon T et al. F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation. Nat Immunol 2012; 13: 651-658.
23. Pushparaj PN, Tay HK, H'ng SC, Pitman N, Xu D, McKenzie A et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 2009; 106: 9773-9778.
24. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007; 179: 2051-2054.
25. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007; 40: 216-225.
26. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoural accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 2014; 134: 1669-1682.
27. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 2011; 56: 3596-3601.
28. Hu LA, Fu Y, Zhang DN, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer. Asian Pac J Cancer Prev 2013; 14: 2563-2566.
29. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010; 5: e10312.
30. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790-13795.
31. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 2008; 3: e1651.
32. Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, Liang SC et al. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap resampling scheme. BMC Genomics 2007; 8: 140.
33. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 2005; 167: 1763-1775.
34. Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2009; 2: 18.
35. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res 2012; 22: 1197-1211.
36. Koshikawa N, Maejima C, Miyazaki K, Nakagawara A, Takenaga K. Hypoxia selects for high-metastatic Lewis lung carcinoma cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumours. Oncogene 2006; 25,: 917-928.
37. Weerasinghe P, Buja LM. Oncosis: an important non-apoptotic mode of cell death. Exp Mol Pathol 2012; 93: 302-308.
38. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell 2012; 48: 158-167.
39. Hail N Jr, Carter BZ, Konopleva M, Andreeff M. Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis 2006; 11: 889-904.
40. Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 2012; 3: 78.
41. Koshikawa N, Iyozumi A, Gassmann M, Takenaga K. Constitutive upregulation of hypoxia-inducible factor-1α mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene 2003; 22: 6717-6724.
42. Takasu M, Tada Y, Wang JO, Tagawa M, Takenaga K. Resistance to apoptosis induced by microenvironmental stresses is correlated with metastatic potential in Lewis lung carcinoma. Clin Exp Metastasis 1999; 17: 409-416.
43. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H et al. ROS-generating mitochondrial DNA mutations can regulate tumour cell metastasis. Science 2008; 320: 661-664.
44. Ishikawa K, Takibuchi G, Kobayashi T, Ishikawa K, Nakada K, Mori M et al. Enhanced glycolysis induced by mtDNA mutations does not regulate metastasis. FEBS Lett 2008;582: 3525-3530.
45. Akimoto M, Nagasawa H, Hori H, Uto Y, Honm Y, Takenaga K. An inhibitor of HIF-α subunit expression suppresses hypoxia-induced dedifferentiation of human NSCLC into cancer stem cell-like cells. World J Med Genet 2013; 3: 41-54.
46. Shimojo Y, Akimoto M, Hisanaga T, Tanaka T, Tajima Y, Honma Y et al. Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells. Clin Exp Metastasis 2013; 30: 143-154.
47. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA 2010; 107: 18581-18586.